DFDA

Concurrent Chemoradiation (Cisplatin-based)

Treatment for Larynx Cancer

Typical Dosage: Cisplatin 100 mg/m2 every 3 weeks for 3 cycles or 40 mg/m2 weekly concurrent with radiation

Effectiveness
85%
Safety Score
25%
Clinical Trials
4
Participants
80K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Cisplatin 100 mg/m2 every 3 weeks for 3 cycles or 40 mg/m2 weekly concurrent with radiation
Time to Effect
Weeks to months
Treatment Duration
5-7 weeks concurrent with radiation
Evidence Quality
HIGH
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$5,000
Monitoring:$8,000
Side Effect Mgmt:$6,000
Total Annual:$60,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$95,000/QALY
QALYs Gained
2.8
Outcome-Based Costs
Cost per Responder
$80,000
Cost per Remission
$92,308
Comparison vs Radiation Therapy alone
Cost Difference
+$20,000/year
More expensive
QALY Difference
+0.30 QALYs
Better outcomes
Dominance
No dominance
Concurrent Chemoradiation (Cisplatin-based) Outcomes

for Larynx Cancer

Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+75%
Remission Rate
+65%
Common Side Effects
Severe mucositis
+75%
Dysphagia
+80%
Nausea and vomiting
+70%
Fatigue
+85%
Myelosuppression (low blood counts)
+60%
Nephrotoxicity (kidney damage)
+30%
Ototoxicity (hearing loss)
+25%

Sources:

oatext.com
cancerconnect.com
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
2 active trials recruiting for Concurrent Chemoradiation (Cisplatin-based) in Larynx Cancer

Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer

NCT06039631RECRUITINGPHASE2
View Study
82 participants
INTERVENTIONAL
Shanghai, China
Started: Aug 22, 2023

Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer

NCT06554028NOT YET RECRUITINGPHASE2
View Study
46 participants
INTERVENTIONAL
Zhengzhou, China
Started: Aug 1, 2024
Completed Clinical Trials
1 completed trial for Concurrent Chemoradiation (Cisplatin-based) in Larynx Cancer

Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)

NCT00095875COMPLETEDPHASE3
View Study
145 participants
INTERVENTIONAL
La Jolla, United States +14 more
Started: Aug 1, 2004